A Phase 2A Clinical Trial to Assess the Safety and Tolerability of ERX1000 in Men and Women for the Treatment of Obesity.
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Monroe Biomedical Research
Louisville, Kentucky, United States
Harold Bays, MDRecruiting - Monroe Biomedical Research
Monroe, North Carolina, United States
Awawu Igbinadolor, MDRecruiting - Monroe Biomedical Research
North Charleston, South Carolina, United States
Gregory J Feldman, MDRecruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 28 May 2026
- Primary completion
- 31 May 2027
- Completion
- 31 May 2027
- Last update posted
- 22 Jun 2026
- Registered enrollment
- 80
- Registry id
- NCT07570758
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.